Form 13-F position report

BIOXCEL THERAPEUTICS INC COM (

Reported by Squarepoint Ops LLC

BTAI CUSIP 09075P105 Manager CIK 0001642575

First reported at 34,257 shares this quarter.

New
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 34,257 Quarter-end amount reported
Reported value $43,849 Fair value at quarter end
Consecutive quarters held 3 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 0
2023-12-31 168398
2024-03-31 0
2024-06-30 43849
2024-09-30 14463
2024-12-31 26938
2025-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

7 quarters
Quarterly reported position history for BIOXCEL THERAPEUTICS INC COM ( held by Squarepoint Ops LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2025 Reduced 0 -72,046 (-100.0%) 0 $0 2025-05-15
Q4 2024 Added 72,046 +48,336 (203.9%) < 0.01% $26,938 2025-02-14
Q3 2024 Reduced 23,710 -10,547 (-30.8%) < 0.01% $14,463 2024-11-14
Q2 2024 New 34,257 +34,257 (0.0%) < 0.01% $43,849 2024-08-14
Q1 2024 Reduced 0 -57,084 (-100.0%) 0 $0 2024-05-15
Q4 2023 New 57,084 +57,084 (0.0%) < 0.01% $168,398 2024-02-14
Q4 2021 Reduced 0 -9,438 (-100.0%) 0 $0 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

95 managers reported BIOXCEL THERAPEUTICS INC COM ( for Q2 2024.

Managers reporting BIOXCEL THERAPEUTICS INC COM ( in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ARMISTICE CAPITAL LLC Added 2,987,000 +2,616,027 0.05% $3,823,360 2 qtrs
FMR LLC Reduced 2,205,172 -288,944 < 0.01% $2,822,621 26 qtrs
VANGUARD GROUP INC Reduced 970,430 -128,945 < 0.01% $1,242,151 26 qtrs
BlackRock Inc Reduced 440,685 -887,376 < 0.01% $564,077 25 qtrs
BNP PARIBAS FINANCIAL MARKETS Added 273,135 +251,385 < 0.01% $349,613 21 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 266,719 -191,201 < 0.01% $341,470 22 qtrs
CHARLES SCHWAB INVESTMENT MANAGEMENT INC Added 203,615 +12,645 < 0.01% $260,627 21 qtrs
NORTHERN TRUST CORPORATION Reduced 194,953 -16,649 < 0.01% $249,540 22 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP Added 173,318 +83,128 < 0.01% $221,847 17 qtrs
WELLS FARGO & COMPANY MN Added 133,676 +10,590 < 0.01% $171,105 25 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
34,257
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.